Abstract
Objective
The objective of the current study was to identify the 100 top-cited studies in cancer immunotherapy.
Materials and methods
A retrospective bibliometric analysis was performed in March 2019. Studies were searched on the Web of Science to identify the 100 top-cited studies in cancer immunotherapy. Studies were identified and analysed for authorship, journal, study type, year of publication and institution.
Results
The 100 top-cited papers were cited from 591 to 5332 times and were published between 1986 and 2016. They were published in 27 journals, and New England Journal of Medicine published most of the studies (n = 14), followed by Nature (n = 11) and Journal of Clinical Oncology (n = 10). They were published from 10 countries, and the USA published most of the studies (n = 82), followed by France (n = 5) and Netherlands (n = 3). National Cancer Institute in USA was the leading institution and Rosenberg, SA was the most productive author.
Conclusions
This study provides insights into development and most important papers in cancer immunotherapy and will provide evidence for future research in cancer immunotherapy.
Introduction
Cancer immunotherapy is a therapy used to combat cancer by involving or using the components of the immune system [Citation1]. The current cancer immunotherapy involves three approaches including the blockage of immune checkpoints, adoptive cellular therapy and vaccination [Citation2–5]. In the past 20 years, significant progress has been achieved in cancer immunotherapy. Notably, the Nobel Prize in Physiology or Medicine 2018 awarded the discovery of cancer immunotherapy [Citation6,Citation7]. Up to now, advancements of cancer immunotherapy are mainly reflected by scientific articles, especially by using the bibliometrics analysis [Citation7].
Bibliometrics is an analysis of written publications such as books and articles [Citation8]. It has been used to quantitative research assessment exercise of academic output and provides evidence for funding [Citation9,Citation10]. Citation analysis is the main bibliometrics method [Citation11]. The number of citations is not only the indicator of the impact of an article in the scientific community but also the basis of impact factor [Citation12]. Highly cited papers are considered as the fundamental of research fields [Citation13,Citation14]. Therefore, analysis of highly cited or top cited articles can provide information about scientific progress and research trends in a specific discipline [Citation12].
There have been some studies which were used to assess the top-cited articles in various research fields, such as tuberculosis [Citation15], diabetes [Citation16], surgery [Citation17], anaesthesiology [Citation18], rehabilitation [Citation19], vaccine [Citation20], etc. However, no such study for cancer immunotherapy has been published. Therefore, we performed the current bibliometric analysis to assess the 100 top-cited articles for cancer immunotherapy.
Materials and methods
This was a retrospective bibliometric analysis which did not involve human subjects [Citation12], thus it was not needed to be approved by the institutional review board.
Search strategy
We performed a search of studies in cancer immunotherapy in Web of Science Core Collection on 10 March 2019. The searched terms included cancer and immunotherapy. All papers since 1945 in the database were searched. The searched results were sorted by citations and articles which had more citations ranked higher [Citation13].
Article selection
Two authors independently screened the abstracts and full-texts to identify the 100 top-cited articles about cancer immunotherapy. Disagreements were resolved by discussion. Only articles that focused on the subject of cancer immunotherapy were included. A cancer immunotherapy article was defined as any study that focused on any immunotherapy for any cancer. Articles about studies conducted using other therapy for cancer but mentioned immunotherapy was excluded. In addition, studies that analysed the immune factors which have potential effect for cancer were also excluded.
Data extraction
After all 100 top-cited articles were selected, data were extracted by two authors [Citation13]. The following data were extracted [Citation13], including title, citation number, publication year, number of authors, name of first author and corresponding author, source journal, impact factor of the journal, article types.
Data analysis
Data analyses were performed to determine study type, country, year of publication, journal title, authorship, institution, as previously described [Citation13]. All of the data were presented by using only descriptive statistics, and no statistical significance tests were performed [Citation12].
Results
The 100 top-cited articles are listed in . The 100 top-cited articles were identified on the basis of their citations, and the number of citations ranged from 591 to 5332 with a total number of citations equal to 103,763 and a median number of citations equal to 812.5.
Table 1. The 100 top-cited studies in cancer immunotherapy.
These papers were published in 27 journals (). The highest number was from the New England Journal of Medicine (n = 14), followed by Nature (n = 11) and Journal of Clinical Oncology (n = 10). Other journals like Science Translational Medicine, Nature Reviews Cancer, Journal of Experimental Medicine, Nature Medicine and Nature Reviews Immunology had at least five but less than 10 articles. The other 19 journals had less than five articles. The impact factors of all the journals ranged from 4.225 to 79.26.
Table 2. Journals of the 100 top-cited studies published.
All articles were published during a span of 31 years from 1986 to 2016 (). The maximum number of articles were published in 2011 and 2012 (n = 9), and for a five-year period, the maximum contribution was made by 2011–2015 (n = 32).
Table 3. Published years of the 100 top-cited studies.
Of all the 100 articles, 72 articles were original articles, 28 were reviews (). Among the 72 original articles, there were 43 basic researches, 28 trials and one case report. The average citations of trials were much higher those of the basic researches.
Table 4. Study types of the 100 top-cited studies.
A total of 10 countries contributed to the top 100 cited articles (). The USA contributed most of the articles with 83 papers, France contributed five papers, while Argentina, China, Australia, Belgium, England, Germany, Japan and Netherlands each contributed less than five studies.
Table 5. Countries of the 100 top-cited studies.
Among the 100 articles, 17 institutions contributed more than one article (). The 17 institutions were from four countries, including USA (n = 14), France (n = 1), Netherlands (n = 1) and Belgium (n = 1). The top four contributors were National Cancer Institute in USA (n = 21), Johns Hopkins University in USA (n = 6), Baylor Institution Immunology Research in USA (n = 4) and French National Institute of Health and Medical Research in France (n = 4).
Table 6. Institutions published at least two 100-top cited studies.
There were 11 authors contributed more than one article as first author, and 12 authors contributed more than one article as the corresponding author (). Rosenberg, SA contributed the highest number of papers as both corresponding author (n = 13) and first author (n = 8).
Table 7. Authors published at least two papers as first author or corresponding author.
Discussion
Given the high burden of cancer, there has been great productivity of cancer research. In the past two decades, cancer immunotherapy is the most promise research field for the treatment of cancer. Although there have been several citation analyses concerning various cancers [Citation117–119], yet there has been no such study for cancer immunotherapy to describe the research trends. Given cancer immunotherapy awarded by Nobel Prize last year, thus, we performed the current study.
The top 100 most-cited articles were published in 33 different journals between 1986 and 2016. New England Journal of Medicine was the most frequent journal in our list, with 14 articles, followed by Nature and Journal of Clinical Oncology. Other top journals include Science Translational Medicine, Nature Reviews Cancer, Journal of Experimental Medicine, Nature Medicine and Nature Reviews Immunology.
Our study encompasses a wide variety of authors, institutions and countries. The USA had a powerful influence, 83% of articles were originated from the institution in that country, whereas the other several countries contributed the remaining papers. When we examined the publications by individual authors, we found Rosenberg SA contributed most of the top-cited papers as first author and corresponding author. It is very surprising that both the two Nobel prize winners James P. Allison and Tasuku Honjo were not listed in top-cited papers as contact author and first author. In the 100 top-cited papers, there were only four papers co-authored by Allison [Citation41,Citation46,Citation89,Citation99], while there was no paper co-authored by Tasuku Honjo. It was possible that their papers might have not so many citations. However, their papers would be cited more time in the next few years, because everyone knows them now and would like to cite their studies.
Like many previous bibliometric analyses, our study also has some limitations [Citation120]. First, citation analysis was based on the Web of Science, citation numbers might be misleading [Citation11,Citation120], owing to self-citations, sub-publications and time of publications, we may have missed some important papers which have been indexed by other databases, such as Scopus and Google [Citation19]. Second, as for the authorship, we only included the first author and corresponding author. It is possible that several authors will have co-authored papers and therefore be underrepresented in the current study [Citation11]. Third, searching based on title and contents means a small number of manuscripts which involving cancer immunotherapy might not have been identified [Citation12].
In conclusion, our study provides a comprehensive list of the true landmark publication in cancer immunotherapy and recognizes contributions made by essential authors, institutions, published scientific journals, research types. Given the high burden of cancer, cancer immunotherapy remains an important research area. Increased research productivity is clearly indicated on numerous fronts of cancer immunotherapy.
Ethics committee approval
This is a bibliometric analysis, so ethics approval is not applicable.
Disclosure statement
No potential conflict of interest was reported by the authors.
Related Research Data
References
- Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–277.
- Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
- Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, et al. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 2016;44:1051–1061.
- Kaiser J, Couzin-Frankel J. Cancer immunotherapy sweeps Nobel for medicine. Science. 2018;362:13.
- Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562:20–21.
- Blakeman K. Bibliometrics in a digital age: help or hindrance. Sci Prog. 2018;101:293.
- Yeung AWK, Heinrich M, Atanasov AG. Ethnopharmacology—a bibliometric analysis of a field of research meandering between medicine and food science? Front Pharmacol. 2018;9:215.
- Tang H, Huang W, Ma J, et al. SWOT analysis and revelation in traditional Chinese medicine internationalization. Chin Med. 2018;13:5.
- Feijoo JF, Limeres J, Fernandez-Varela M, et al. The 100 most cited articles in dentistry. Clin Oral Invest. 2014;18:699–706.
- Kim HJ, Yoon DY, Kim ES, et al. The 100 most-cited articles in neuroimaging: a bibliometric analysis. Neuroimage. 2016;139:149–156.
- Yin X, Cheng F, Wang X, et al. Top 100 cited articles on rheumatoid arthritis: a bibliometric analysis. Medicine (Baltimore). 2019;98:e14523.
- Yoon SJ, Yoon DY, Ja Lim K, et al. The 100 top-cited articles focused on magnetic resonance: a bibliometric analysis. Acta Radiol. 2019;60:710–715.
- Zhang Y, Huang J, Du L. The top-cited systematic reviews/meta-analyses in tuberculosis research: a PRISMA-compliant systematic literature review and bibliometric analysis. Medicine (Baltimore). 2017;96:e4822.
- Zhao X, Guo L, Lin Y, et al. The top 100 most cited scientific reports focused on diabetes research. Acta Diabetol. 2016;53:13–26.
- Nayar SK, Dein EJ, Bernard JA, et al. Basic science research trends in orthopedic surgery: an analysis of the top 100 cited articles. HSS J. 2018;14:333–337.
- Zhang Z, Van Poucke S, Goyal H, et al. The top 2,000 cited articles in critical care medicine: a bibliometric analysis. J Thorac Dis. 2018;10:2437–2447.
- Kreutzer JS, Agyemang AA, Weedon D, et al. The top 100 cited neurorehabilitation papers. NeuroRehabilitation. 2017;40:163–174.
- Zhang Y, Quan L, Xiao B, et al. The 100 top-cited studies on vaccine: a bibliometric analysis. Hum Vac Immunother. 2019. doi: 10.1080/21645515.2019.1614398.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
- Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
- Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.
- Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–915.
- Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854.
- Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
- Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733.
- Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129.
- Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321–327.
- Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–2199.
- Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
- Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318–1321.
- Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175.
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
- West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898–905.
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–274.
- Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096–1103.
- Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538–18543.
- Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666.
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;3;348:69–74.
- Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562.
- Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–2357.
- Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
- Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. PNAS. 2003;100:8372–8377.
- Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–365.
- Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–5218.
- Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756–2761.
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
- Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655.
- Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–384.
- Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297–1302.
- Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–4506.
- Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51.
- Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
- Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669.
- Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
- Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–851.
- Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–4557.
- Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907.
- Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.
- Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.
- Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306.
- Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677–685.
- Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271.
- Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696.
- Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–970.
- Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269–281.
- Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458–6462.
- Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–924.
- Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713–716.
- Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758.
- Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.
- Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;1;183:87–97.
- Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994;73:2432–2443.
- Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535–546.
- Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109.
- Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–3094.
- Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–1616.
- Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180:347–352.
- Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720.
- Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1272–1278.
- Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22.
- Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129.
- Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648.
- Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;1;179:921–930.
- Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–567.
- Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581.
- Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941–952.
- Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–251.
- Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84–88.
- Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451–6458.
- Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
- Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270.
- Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137–1146.
- Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–1166.
- Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377.
- Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712–4717.
- Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–211.
- Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147–1154.
- Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164.
- Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–1271.
- Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–1683.
- Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–4828.
- Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–1105.
- Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829.
- Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–580.
- Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
- Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4 + CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336–344.
- Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–327.
- Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682–685.
- Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
- Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–2593.
- Gattinoni L, Powell DJ Jr., Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–393.
- Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.
- Iqbal U, Rehan A, Akmal M, et al. Top 100 most influential articles in the field of myeloid neoplasms: a bibliometric study. Acta Haematol. 2019;141:68–78.
- Jusue-Torres I, Hulbert A, Germanwala AA, et al. The 100 most-cited reports about craniopharyngioma. World Neurosurg. 2018;119:e910–e921.
- Uysal E. Top 100 cited classic articles in breast cancer research. Eur J Breast Health. 2017;13:129–137.
- Ullah W, Abdullah HMA, Ahmad E, et al. A bibliometric analysis of the top 100 cited articles on hepatic magnetic resonance imaging. Cureus. 2018;10:e2733.